Cargando…

LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases

INTRODUCTION: Leptomeningeal metastases (LM) is a clinical complication that occurs when cancer cells invade the leptomeninges and cerebrospinal fluid of patients with malignant tumors. Once diagnosed, limited treatment options exist, and survival is poor. Rhenium-186 Nanoliposome ((186)RNL) is a li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerra-Garcia, Maria, Balinda, Henriette, Bao, Ande, Garcia, Michael, Gilbert, Andrea, Phillips, William, Floyd, John, Brenner, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351288/ http://dx.doi.org/10.1093/noajnl/vdab071.039

Ejemplares similares

LMD-13. ReSPECT-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Brenner, Andrew, et al.
Publicado: (2021)

LOCL-04 SAFETY AND FEASIBILITY OF RHENIUM-186 NANOLIPOSOME (186RNL) IN LEPTOMENINGEAL METASTASES [LM] PHASE 1/2A DOSE ESCALATION TRIAL
por: Brenner, Andrew, et al.
Publicado: (2022)

LMAP-21 PRELIMINARY CLINICAL DATA IN THE PHASE 1/2A DOSE ESCALATION TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN LEPTOMENINGEAL METASTASES (LM): THE RESPECT-LM TRIAL
por: Youssef, Michael, et al.
Publicado: (2023)

TIPS-23 SAFETY AND FEASIBILITY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF RHENIUM (186RE) OBISBEMEDA (186RNL) IN RECURRENT GLIOMA: THE RESPECT-GBM TRIAL
por: Brenner, Andrew, et al.
Publicado: (2023)

TIPS-22 A TWO-PART, PHASE 1 STUDY OF RHENIUM (186RE) OBISBEMEDA (186RNL) DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) FOR RECURRENT, REFRACTORY, OR PROGRESSIVE CHILDHOOD EPENDYMOMA AND HIGH-GRADE GLIOMA (HGG)
por: Plant, Ashley, et al.
Publicado: (2023)

EPCT-18. A TWO-PART, PHASE 1 STUDY OF RHENIUM-186 NANOLIPOSOME (186RNL) DELIVERED BY CONVECTION ENHANCED DELIVERY FOR RECURRENT, REFRACTORY, OR PROGRESSIVE EPENDYMOMA AND HIGH-GRADE GLIOMA (HGG) AND NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Plant, Ashley, et al.
Publicado: (2021)

LMD-22. Clinicopathological spectrum of leptomeningeal metastases: A 3 year retrospective study
por: Pahwa, Saloni, et al.
Publicado: (2021)

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)

LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021)

LMD-04. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review
por: Mitsuya, Koichi, et al.
Publicado: (2021)

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
por: Bander, Evan D, et al.
Publicado: (2021)

LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma
por: Lowe, Stephen, et al.
Publicado: (2021)

Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases
por: Khaled, Mariam Lotfy, et al.
Publicado: (2023)

LMD-18. Detection and serial monitoring of CSF ctDNA in breast cancer leptomeningeal disease (BCLM)
por: Fitzpatrick, Amanda, et al.
Publicado: (2021)

LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients
por: Takayesu, Jamie, et al.
Publicado: (2021)

LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2021)

BSCI-01 INTRATHECAL DELIVERY OF DENDRITIC CELL VACCINE ERADICATES TUMOR GROWTH AND PROTECTS AGAINST LEPTOMENINGEAL DISEASE (LMD) RE-INOCULATION IN IMMUNOCOMPETENT HER2+ AND TRIPLE NEGATIVE BREAST CANCER (TNBC) LMD XENOGRAFT MODELS
por: Law, Vincent, et al.
Publicado: (2022)

LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease
por: Najem, Hinda, et al.
Publicado: (2021)

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)
por: Ferguson, Sherise D., et al.
Publicado: (2022)

Subject index for volume 186
Publicado: (1992)

Health Tract, No. 186: Deranged
Publicado: (1864)

Health Tract, No. 186: Deranged
Publicado: (1865)

Rhenium‐186‐mercaptoacetyltriglycine‐labeled Monoclonal Antibody for Radioimmunotherapy: In vitro Assessment, in vivo Kinetics and Dosimetry in Tumor‐bearing Nude Mice
por: Kinuya, Seigo, et al.
Publicado: (1998)

$\gamma$-vibrational bands in $^{186}$Hg
por: Ibrahim, F, et al.
Publicado: (1993)

The s-process branching at $^{186}Re$ revised
por: Mohr, P, et al.
Publicado: (2006)

Bonding Cables in DSF Cleanroom 186
por: Ordan, Julien Marius
Publicado: (2018)

RnlB Antitoxin of the Escherichia coli RnlA-RnlB Toxin–Antitoxin Module Requires RNase HI for Inhibition of RnlA Toxin Activity
por: Naka, Kenta, et al.
Publicado: (2017)

Measurement of the spectroscopic quadrupole moment of $^{186}$Au: experimental verification of the large prolate deformation of the $^{186}$Au ground state
por: Hinfurtner, B, et al.
Publicado: (1991)

Abstract 186: CD36 Antagonism Minimizes Skin Scarring By Inhibiting JUN-dependent Fibrotic Pathways Within Fibrogenic Fibroblast Subpopulations
por: Borrelli, Mimi R., et al.
Publicado: (2020)

HF fibre stuffing in building 186 at CERN
por: Tiziano Camporesi
Publicado: (2003)

Interaction of stopped antiprotons with nuclei (PS186)
por: Kanert, W, et al.
Publicado: (1985)

Cumulative subject index volumes 186–191
Publicado: (1992)

186. Klebsiella aerogenes: Are there implications to taxonomic accuracy?
por: Herrera, Lauren Nicholas, et al.
Publicado: (2022)

LMD-06. A NSCLC patient with leptomeningeal metastasis harboring rare EGFR mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report
por: Wang, Hui, et al.
Publicado: (2021)

48218 Preclinical modeling of BRAF(V600E)/PTEN-/- melanoma leptomeningeal disease (LMD) to assess intrathecal checkpoint blockade
por: Guerrieri, Renato A., et al.
Publicado: (2021)

LMD-15. Beyond cytologY - A single institution experience using CNSide(TM) for diagnosing and monitoring treatment response in Non-Small Cell Lung Cancer patients with Leptomeningeal Carcinomatosis (LMC)
por: Akerley, Wallace, et al.
Publicado: (2021)

LMD-01. Quantifying intrathecal drug delivery utilizing programmable ventriculoperitoneal shunts
por: McThenia, Sheila, et al.
Publicado: (2021)

Decay studies of the long-lived states in $^{186}$Tl
por: Stryjczyk, M., et al.
Publicado: (2020)

ODP186 Difficulties in diagnosing MODY: clinical case
por: Volkova, Natalya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_br9sft55kug7q78jcv4s7iem5c